ETH Zurich spin-out seeks collaboration for chronic disease research

Seeking collaboration, licensing

ETH Zurich spin-out company, Cytos Biotechnology AG, is looking for partnerships to join their research and development of treatments for chronic diseases similar to the recently announced exclusive license agreement to develop a vaccine against nicotine addiction.

“Our business focuses on highly innovative research and development of a new class of medicines for chronic disease treatment and prevention. We aim to achieve proof-of-concept in man (e.g. phase II) for several vaccine candidates and thereafter advance them beyond clinical development to the market in collaboration with large pharmaceutical companies. With a hand-over of product candidates after proof-of-concept in phase II, we believe the strengths of both industries, small Biotech and big Pharma, are combined most effectively. Establishing such valuable partnerships will remain our goal for the next years,” said Dr. Claudine Blaser of Cytos Biotechnology AG.

Cytos Biotechnology has built a scientific network with several academic research institutions in the world. Through these contacts that involve grants funded by the Swiss Commission for Technology and Innovation (Kommission für Technologie und Innovation (KTI)) and European Union research collaborations as well as informal contacts, Cytos Biotechnology has prime access to cutting edge science, disease specific know-how, and additional specimens and research materials. Among the network partners of Cytos Biotechnology are:

University of Zurich, Switzerland

ETH Zurich, Switzerland 

Justus Liebig Universität Giessen, Germany 

University of Latvia, Riga, Latvia 

Institute of Biotechnology, Vilnius, Lithuania   

University of Freiburg, Germany

University of Milano, Italy

University Pierre et Marie Curie, Paris, France

University of Munich, Germany

University of Basel, Switzerland   

Cytos Biotechnology was spun-out of the Swiss Federal Institute of Technology (ETH) in Zurich in 1995.  Located in Schlieren, Zurich, the company has 129 employees and has been listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.